Antibodies to canine and feline oncostatin M receptor beta and uses thereof

1. An isolated antibody, or antigen-binding portion thereof that specifically binds to canine or feline Oncostatin M receptor Beta (OSMR-β) or both, comprising a combination of complementary determining region (CDR) sequences selected from the group consisting of:

1) 02D09: variable heavy (VH)-CDR1 of SEQ ID NO: 1

(DYGMH),

VH-CDR2 of SEQ ID NO: 2 (YISSGSRAVFFADTVKG),

VH-CDR3 of SEQ ID NO: 3 (DRYDGRGFAY),

variable light (VL)-CDR1 of SEQ ID NO: 4

(RASQSISNNLH),

VL-CDR2 of SEQ NO: 5 (YASQSIS), and

VL-CDR3 of SEQ ID NO: 6 (QQSNSWPLT);

2) 09E09: VH-CDR1 of SEQ ID NO: 7 (SYAMS),

VH-CDR2 of SEQ ID NO: 8 (YISSGGDYIYYADTVKG),

VH-CDR3 of SEQ ID NO: 9 (DPITGTFAY),

VL-CDR1 of SEQ ID NO: 10 (RASQDINNYLN),

VL-CDR2 of SEQ ID NO: 11 (YTSTLHS), and

VL-CDR3 of SEQ ID NO: 12 (QQGNTLPWT);

3) 10F07: VH-CDR1 of SEQ ID NO: 13 (SYAMS),

VH-CDR2 of SEQ ID NO: 14 (YISSGGDYFYYADTVKG),

VH-CDR3 of SEQ ID NO: 15 (DPITGTFAY),

VL-CDR1 of SEQ ID NO: 16 (RASQDITNYLN),

VL-CDR2 of SEQ ID NO: 17 (YTSTLHS), and

VL-CDR3 of SEQ ID NO: 18 (QQGHMLPWT);

4) 14C04: VH-CDR1 of SEQ ID NO: 19 (NYWMN),

VH-CDR2 of SEQ ID NO: 20 (QIYPGHVNTNYNGNFKD),

VH-CDR3 of SEQ ID NO: 21 (SADNSGFVLFAY), 

VL-CDR1 of SEQ ID NO: 22 (RASKSVSTSGYSYLH),

VL-CDR2 of SEQ ID NO: 23 (LASNLES), and

VL-CDR3 of SEQ ID NO: 24 (QHSRELPLT);

5) 19F07: VH-CDR1 of SEQ ID NO: 25 (DYYMA),

VH-CDR2 of SEQ ID NO: 26 (NINYDGSSTYYLDSLKS),

VH-CDR3 of SEQ ID NO: 27 (GLTWDFDV), 

VL-CDR1 of SEQ ID NO: 28 (KASQDVDTAVA), 

VL-CDR2 of SEQ ID NO: 29 (LASTRHT), and

VL-CDR3 of SEQ ID NO: 30 (QQYSRFPLT);

or

6) CDR variants of 1, 2, 3, 4, or 5.

2. The antibody, or antigen-binding portion thereof of claim 1 , wherein the antibody antagonizes IL-31-mediated signaling or OSM-mediated signaling or both in a canine and/or feline cell.

3. The antibody, or antigen-binding portion thereof of claim 2 , wherein the antibody antagonizes both IL-31-mediated signaling and OSM-mediated signaling in a canine and/or feline cell.

4. The antibody of claim 1 , comprising at least one of the group consisting of:

(a) a variable heavy chain comprising

(MU_02D09_VH)

SEQ ID NO: 31

EVQLVESGGGLVKPGGSLTLSCAASGFTFSDYGMHWLRQAPEKGLEWVAYISSGSRAVFFAD

TVKGRFTISRDNAKNTLFLQMTSLRSDDTAMYYCARDRYDGRGFAYWGQGTLVTVSA,

(MU_09E09_VH)

SEQ ID NO: 35

DVKLVESGEGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVAYISSGGDYIYYADT

VKGRFTISRDNARNTLYLQMSSLKSEDTAMYYCTRDPITGTFAYWGQGTLVTVSA,

(MU_10F07_VH)

SEQ ID NO: 39

DVKLVESGEGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVTYISSGGDYFYYAD

TVKGRFTISRDNARNTLYLQMSSLKSEDTAMYYCTRDPITGTFAYWGQGTLVTVSA,

(MU_14C04_VH)

SEQ ID NO: 43

EVQLQESGAELVKPGASVKISCKASGYAFSNYWMNWMKQRPGKGLEWIGQIYPGHVNTNYN

GNFKDKATLTADKSSSTAYMQLSSLTSEDSAVYFCARSADNSGFVLFAYWGQGTLVTVS,

(MU_19F07_VH)

SEQ ID NO: 47

EVKLVESEGGLVQPGSSMKLSCTASGFTFSDYYMAWVRQVPEKGLEWVANINYDGSSTYYLD

SLKSRFIISRDNAKNILYLQMSSLKSEDTATYYCARGLTWDFDVWGTGTTVTVSS,

(FEL_02D09_VH1)

SEQ ID NO: 51

DVQLVESGGDLVKPGGSLRLTCVASGFTYSDYGMHWVRQAPGKGLQWVAYISSGSRAVFFA

DTVKGRFTISRDNAKNTLYLQMNSLKTEDTATYYCVRDRYDGRGFAYWGQGTLVTVSS,

(FEL_02D09_VH2)

SEQ ID NO: 53

DVQLVESGGDLVKPGGSLRLTCVASGFTFSDYGMHWVRQAPGKGLQWVAYISSGSRAVFFA

DTVKGRFTISRDNAKNTLYLQMNGLRTEDTATYYCARDRYDGRGFAYWGQGTLVTVSS,

(CAN_09E09_VH1)

SEQ ID NO: 59

EVQLVESGGDLVKPGGSLRLSCVASGFTFSSYAMSWVRQAPGKGLQWVAYISSGGDYIYYAD

TVKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRDPITGTFAYWGQGTLVTVSS,

(CAN_09E09_VH2)

SEQ ID NO: 61

EVQLVESGGDLVKPAGSLTLSCLASGFTFSSYAMSWVRQTPEKGLQWVAYISSGGDYIYYADT

VKGRFTISRDNAKNTLYLQMNSLRDEDTAVYYCARDPITGTFAYWGQGTLVTVSS,

(FEL_09E09_VH1)

SEQ ID NO: 67

DVQLVESGGDLVKPGGSLRLTCVASGFTYSSYAMSWVRQAPGKGLQWVAYISSGGDYIYYAD

TVKGRFTISRDNAKNTLYLQMNSLKTEDTATYYCVRDPITGTFAYWGQGTLVTVSS,

(FEL_09E09_VH2)

SEQ ID NO: 69

DVQLVESGGNLVKPGGSLRLTCVASGFTFSSYAMSWVRQAPGKGLQWVAYISSGGDYIYYAD

TVKGRFTISKDNAKNTLYLQMNSLKTEDTATYYCARDPITGTFAYWGQGTLVTVSS,

(CAN_10F07_VH1)

SEQ ID NO: 75

EVQLVESGGDLVKPGGSLRLSCVASGFTFSSYAMSWVRQAPGKGLQWVAYISSGGDYFYYA

DTVKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRDPITGTFAYWGQGTLVTVSS,

(CAN_10F07_VH2)

SEQ ID NO: 79

EVQLVESGGDLVKPAGSLTLSCLASGFTFSSYAMSWVRQTPEKGLQWVAYISSGGDYFYYAD

TVKGRFTISRDNAKNTLYLQMNSLRDEDTAVYYCARDPITGTFAYWGQGTLVTVSS,

(FEL_10F07_VH1)

SEQ ID NO: 83

DVQLVESGGDLVKPGGSLRLTCVASGFTYSSYAMSWVRQAPGKGLQWVAYISSGGDYFYYA

DTVKGRFTISRDNAKNTLYLQMNSLKTEDTATYYCVRDPITGTFAYWGQGTLVTVSS,

(FEL_10F07_VH2)

SEQ ID NO: 87

DVQLVESGGDLVKPGGSLRLTCVASGFTFSSYAMSWVRQAPGKGLQWVAYISSGGDYFYYA

DTVKGRFTISRDDAKNTLYLQMSSLKTEDTATYYCTGDPITGTFAYWGQGTLVTVSS,

(CAN_19F07_VH1)

SEQ ID NO: 91

EVQLVESGGDLVKPGGSLRLSCVASGFTFSDYYMAWVRQAPGKGLQWVANINYDGSSTYYLD

SLKSRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRGLTWDFDVWGQGTLVTVSS,

(CAN_19F07_VH2)

SEQ ID NO: 95

EVQLVESGGDLVKPAGSLTLSCLASGFTFSDYYMAWVRQTPEKGLQWVANINYDGSSTYYLD

SLKSRFTISRDNAKNTLYLQMNSLRDEDTAVYYCARGLTWDFDVWGQGTLVTVSS,

(FEL_19F07_VH1)

SEQ ID NO: 99

DVQLVESGGDLVKPGGSLRLTCVASGFTYSDYYMAWVRQAPGKGLQWVANINYDGSSTYYL

DSLKSRFTISRDNAKNTLYLQMNSLKTEDTATYYCVRGLTWDFDVWGQGTLVTVSS,

(FEL_19F07_VH2)

SEQ ID NO: 103

DVQLVESGGNLVKPGGSLRLTCVASGFTFSDYYMAWVRQAPGKGLQWVANINYDGSSTYYLD

SLKSRFTISRDNAKNTLYLQMNSLKTEDTATYYCARGLTWDFDVWGQGTLVTVSS,

(CAN_14C04_VH1)

SEQ ID NO: 127

EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYWMNWVRQAPGKGLQWVAQIYPGHVNTNYN

GNFKDRFTISRDNARNTVYLQMNSLRAEDTAVYYCARSADNSGFVLFAYWGQGTLVTVSS,

or

(CAN_14C04_VH2)

SEQ ID NO: 129

EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYWMNWVRQSPGKGLQWVAQIYPGHVNTNYN

GNFKDRFTISRDNAKNTLYLQMNSLRAEDTAVYFCARSADNSGFVLFAYWGQGTLVTVSS;

and

(b) a variable light chain comprising

(MU_02D09_VL)

SEQ ID NO: 33

DIVLTQSPATLSVTPGDSVSLSCRASQSISNNLHWYQQTSHESPRLLITYASQSISGIPSRFSGS

GSGTDFTLSINSVETEDFGMYFCQQSNSWPLTFGAGTKLELK,

(MU_09E09_VL)

SEQ ID NO: 37

DLQMTQTTSSLSASLGDRVTISCRASQDINNYLNWYQQKPDGTVKLLIYYTSTLHSGVPSRFSG

SGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFGGGTKLEIK,

(MU_10F07_VL)

SEQ ID NO: 41

DIQMTQTTSSLSASLGDRVTISCRASQDITNYLNWYQQKPDGTVKLLIYYTSTLHSGVPSRFSG

SGSGTDFSLTISNLEQEDIATYFCQQGHMLPWTFGGGTKLEIK,

(MU_14C04_VL)

SEQ ID NO: 45

DIVLTQSPASLAVSLGQRATISCRASKSVSTSGYSYLHWYQQKPGQPPKLLIFLASNLESGVPA

RFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPLTFGAGTKLELK,

(MU_19F07_VL)

SEQ ID NO: 49

DIVMTQSHKFMSPSVGDRVSITCKASQDVDTAVAWYQQKPGQSPKWYLASTRHTGVPDRFT

GSGSGTDFTLTISNVQSEDLADYFCQQYSRFPLTFGAGTKLELK,

(FEL_02D09_VL1)

SEQ ID NO: 55

EIQMTQSPSSLSASPGDRVTITCRASQSISNNLHWYQQKPGKVPKLLIYYASQSISGVPSRFSG

SGSGTDFTLTISSLEPEDAATYYCQQSNSWPLTFGQGT,

(FEL_02D09_VL2)

SEQ ID NO: 57

DIVMTQTPLSLSVTPGESASISCRASQSISNNLHWYLQKSGQSPRRLIYYASQSISGVPDRFSG

SGSGTDFTLRISRVEADDVGVYYCQQSNSWPLTFGQGT,

(CAN_09E09_VL1)

SEQ ID NO: 63

EIVMTQSPASLSLSQEEKVTITCRASQDINNYLNWYQQKPGQAPKLLIYYTSTLHSGVPSRFSG

SGSGTDFSFTISSLEPEDVAVYYCQQGNTLPWTFGQGT,

(CAN_09E09_VL2)

SEQ ID NO: 65

DIVLTQPTSVSGSLGQRVTISCRASQDINNYLNWYQQLPGKAPKLLVYYTSTLHSGVPDRFSGS

NSGSSATLTITGLQAEDEADYYCQQGNTLPWTFGQGT,

(FEL_09E09_VL1)

SEQ ID NO: 71

EIQMTQSPSSLSASPGDRVTITCRASQDINNYLNWYQQKPGKVPKLLIYYTSTLHSGVPSRFSG

SGSGTDFTLTISSLEPEDAATYYCQQGNTLPWTFGQGT,

(FEL_09E09_VL2)

SEQ ID NO: 73

DITMTQSPGSLAGSPGQQVTMNCRASQDINNYLNWYQQKPGQHPKLLIYYTSTLHSGVPDRF

SGSGSGTDFTLTISNLQAEDVASYYCQQGNTLPWTFGQGT,

(CAN_10F07_VL1)

SEQ ID NO: 77

EIVMTQSPASLSLSQEEKVTITCRASQDITNYLNWYQQKPGQAPKLLIYYTSTLHSGVPSRFSG

SGSGTDFSFTISSLEPEDVAVYYCQQGHMLPWTFGQGT,

(CAN_10F07_VL2)

SEQ ID NO: 81

DIVLTQPTSVSGSLGQRVTISCRASQDITNYLNWYQQLPGKAPKLLVYYTSTLHSGVPDRFSGS

NSGSSATLTITGLQAEDEADYYCQQGHMLPWTFGQGT,

(FEL_10F07_VL1)

SEQ ID NO: 85

EIQMTQSPSSLSASPGDRVTITCRASQDITNYLNWYQQKPGKVPKLLIYYTSTLHSGVPSRFSG

SGSGTDFTLTISSLEPEDAATYYCQQGHMLPWTFGQGT,

(FEL_10F07_VL2)

SEQ ID NO: 89

DITMTQSPGSLAGSPGQQVTMNCRASQDITNYLNWYQQKPGQHPKLLIYYTSTLHSGVPDRFS

GSGSGTDFTLTISNLQAEDVASYYCQQGHMLPWTFGQGT,

(CAN_19F07_VL1)

SEQ ID NO: 93

EIVMTQSPASLSLSQEEKVTITCKASQDVDTAVAWYQQKPGQAPKWYLASTRHTGVPSRFSG

SGSGTDFSFTISSLEPEDVAVYYCQQYSRFPLTFGQGT,

(CAN_19F07_VL2)

SEQ ID NO: 97

DIVMTQTPLSLSVSPGETASISCKASQDVDTAVAWFRQKPGQSPQRLIYLASTRHTGVPDRFS

GSGSGTDFTLRISRVEADDTGVYYCQQYSRFPLTFGQGT,

(FEL_19F07_VL1)

SEQ ID NO: 101

EIQMTQSPSSLSASPGDRVTITCKASQDVDTAVAWYQQKPGKVPKLLIYLASTRHTGVPSRFS

GSGSGTDFTLTISSLEPEDAATYYCQQYSRFPLTFGQGT,

(FEL_19F07_VL2)

SEQ ID NO: 105

DITMTQSPGSLAGSPGQQVTMNCKASQDVDTAVAWYQQKPGQHPKWYLASTRHTGVPDRF

SGSGSGTDFTLTISNLQAEDVASYYCQQYSRFPLTFGQGT,

(CAN_14C04_VL1)

SEQ ID NO: 131

EIVMTQSPASLSLSQEEKVTITCRASKSVSTSGYSYLHWYQQKPGQAPKLLIYLASNLESGVPS

RFSGSGSGTDFSFTISSLEPEDVAVYYCQHSRELPLTFGQGT,

or

(CAN_14C04_VL2)

SEQ ID NO: 133

DIVMTQTPLSLSVSPGETASISCRASKSVSTSGYSYLHWYLQKPGQSPQLLIYLASNLESGVSK

RFSGSGSGTDFTLRISRVEADDTGIYYCQHSRELPLTFGQGT.

5. The antibody of claim 1 , wherein the antibody is chimeric.

6. The antibody of claim 1 , wherein the antibody is caninized or felinized.

7. The antibody of claim 1 , wherein the antibody inhibits or neutralizes an IL-31-mediated or OSM-mediated pruritic or allergic condition in a dog or cat, wherein the IL-31-mediated or OSM-mediated pruritic or allergic condition is selected from the group consisting of atopic dermatitis, allergic dermatitis, and pruritis.

8. The antibody of claim 7 , wherein the IL-31-mediated or OSM-mediated pruritic condition is selected from the group consisting of atopic dermatitis and pruritis.

9. A veterinary composition comprising a therapeutically effective amount of the antibody of claim 1 .